Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: an individual patient-data pooled analysis of 11 trials
Open Access
- 1 September 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 30 (18) , 2193-2203
Abstract
Thrombectomy in patients with ST-elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) is associated to better myocardial reperfusion. However, no single trial was adequately powered to asses the impact of thrombectomy on long-term clinical outcome and to identify patients at higher benefit. Thus, we sought to assess these issues in a collaborative individual patient-data pooled analysis of randomized studies (study acronym: ATTEMPT, number of registration: NCT00766740). Individual data of 2686 patients enrolled in 11 trials entered the pooled analysis. Primary endpoint of the study was all-cause mortality. Major adverse cardiac events (MACE) were considered as the occurrence of all-cause death and/or target lesion/vessel revascularization and/or myocardial infarction (MI). Subgroups analysis was planned according to type of thrombectomy device (manual or non-manual), diabetic status, IIb/IIIa-inhibitor therapy, ischaemic time, infarct-related artery, pre-PCI TIMI flow. Clinical follow-up was available in 2674 (99.6%) patients at a median of 365 days. Kaplan–Meier analysis showed that allocation to thrombectomy was associated with significantly lower all-cause mortality (P = 0.049). Thrombectomy was also associated with significantly reduced MACE (P = 0.011) and death + MI rate during the follow-up (P = 0.015). Subgroups analysis showed that thrombectomy is associated to improved survival in patients treated with IIb/IIIa-inhibitors (P = 0.045) and that the survival benefit is confined to patients treated in manual thrombectomy trials (P = 0.011). The present large pooled analysis of randomized trials suggests that thrombectomy (in particular manual thrombectomy) significantly improves the clinical outcome in patients with STEMI undergoing mechanical reperfusion and that its effect may be additional to that of IIb/IIIa-inhibitors.Keywords
This publication has 35 references indexed in Scilit:
- Myocardial No-Reflow in HumansJACC, 2009
- The Emerging Role of Thrombus Aspiration in the Management of Acute Myocardial InfarctionCirculation, 2008
- Adjunctive devices in primary or rescue PCI: A meta-analysis of randomized trialsInternational Journal of Cardiology, 2008
- Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trialsThe Lancet, 2003
- Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarctionEuropean Heart Journal, 2002
- No-Reflow PhenomenonCirculation, 2002
- The “no-reflow” phenomenon: basic science and clinical correlatesHeart, 2002
- Extent of ST-segment deviation in a single electrocardiogram lead 90 min after thrombolysis as a predictor of medium-term mortality in acute myocardial infarctionThe Lancet, 2001
- Relationship of TIMI Myocardial Perfusion Grade to Mortality After Administration of Thrombolytic DrugsCirculation, 2000
- Angiographic Assessment of Myocardial Reperfusion in Patients Treated With Primary Angioplasty for Acute Myocardial InfarctionCirculation, 1998